

## 1 **Epidemiological characteristics of the B.1.526 SARS-CoV-2 variant**

2 Wan Yang,<sup>1\*</sup> Sharon K. Greene,<sup>2</sup> Eric R. Peterson,<sup>2</sup> Wenhui Li,<sup>3</sup> Robert Mathes,<sup>2</sup> Laura Graf,<sup>2</sup>  
3 Ramona Lall,<sup>2</sup> Scott Hughes,<sup>4</sup> Jade Wang,<sup>4</sup> Anne Fine<sup>2, #</sup>

4  
5 <sup>1</sup>Department of Epidemiology, Mailman School of Public Health, Columbia University;

6 <sup>2</sup>Bureau of Communicable Disease, New York City Department of Health and Mental Hygiene;

7 <sup>3</sup>Bureau of Vital Statistics, New York City Department of Health and Mental Hygiene;

8 <sup>4</sup>Public Health Laboratory, New York City Department of Health and Mental Hygiene

9 \* Corresponding author: [wy2202@cumc.columbia.edu](mailto:wy2202@cumc.columbia.edu)

10 #current affiliation: Council of State and Territorial Epidemiologists

11

### 12 **Abstract:**

13 To characterize the epidemiological properties of the B.1.526 SARS-CoV-2 variant of interest,  
14 here we utilized nine epidemiological and population datasets and model-inference methods to  
15 reconstruct SARS-CoV-2 transmission dynamics in New York City, where B.1.526 emerged.  
16 We estimated that B.1.526 had a moderate increase (15-25%) in transmissibility and could  
17 escape immunity in 0-10% of previously infected individuals. In addition, B.1.526 substantially  
18 increased the infection-fatality risk (IFR) among adults 65 or older by >60% during Nov 2020 –  
19 Apr 2021, compared to baseline risk estimated for preexisting variants. Overall, findings suggest  
20 that new variants like B.1.526 likely spread in the population weeks prior to detection and that  
21 partial immune escape (e.g., resistance to therapeutic antibodies) could offset prior medical  
22 advances and increase IFR. Early preparedness for and close monitoring of SARS-CoV-2  
23 variants, their epidemiological characteristics, and disease severity are thus crucial to COVID-19  
24 response as it remains a global public health threat.

25

### 26 **Main Text:**

## 27 **INTRODUCTION**

28 The SARS-CoV-2 virus spread quickly worldwide in early 2020, causing the COVID-19  
29 pandemic. As the virus spread, it also diversified, and multiple novel SARS-CoV-2 variants  
30 emerged in different populations, producing both local and global waves of infection. Several  
31 variants have been characterized as variants of concern (VOC) or of interest (VOI), based on  
32 evidence regarding their ability to increase transmissibility, evade immunity conferred by either  
33 prior infection or vaccination, or cause more severe disease. Accurately estimating the  
34 epidemiological characteristics and impact of these variants is thus important for informing  
35 public health response, such as monitoring effectiveness of vaccines and therapeutic antibodies.  
36 More broadly, such findings can also provide insights into the long-term trajectory of SARS-  
37 CoV-2 beyond the pandemic phase.

38  
39 The B.1.526 variant (WHO designation: Iota)(1), a SARS-CoV-2 VOI, was identified during  
40 Nov 2020 and quickly became a predominant variant in the New York City (NYC) area (2-4). It  
41 has also been detected in all 52 states/territories in the US and at least 27 other countries  
42 (GISAID data (5), as of 6/9/2021). An initial laboratory study (2) suggested that this variant is to  
43 some extent resistant to two therapeutic monoclonal antibodies in clinical use and neutralization  
44 by convalescent plasma and vaccinee sera. However, another study (4) examined all sequenced  
45 B.1.526 cases in NYC identified as of April 5, 2021 (n = 3,679) and showed preliminary  
46 evidence that this variant did not increase risk for infection after vaccination or reinfection. Both  
47 studies may be limited due to the small number of specimens available for analysis as well as  
48 delay in observation and reporting. Given these discrepancies, here we utilize detailed population  
49 epidemiological data collected since the beginning of the COVID-19 pandemic in NYC (March  
50 1, 2020 – April 30, 2021) and multiple model-inference methods to estimate the transmissibility,  
51 immune escape potential, and disease severity of B.1.526. Of note, we include the combination  
52 of B.1.526-S:E484K and B.1.526-S:S477N as B.1.526.

53  
54 As shown in Fig 1 (overall study design), we first apply a network model-inference system to  
55 reconstruct underlying SARS-CoV-2 transmission dynamics in NYC, accounting for under-  
56 detection of infection. This analysis allows estimation of key population variables and  
57 parameters (e.g., the infection rate including those not detected as cases and transmission rate) at  
58 the neighborhood-level as well as citywide. As such, we are able to examine in detail the  
59 epidemiological dynamics in Washington Heights – Inwood (WHts), the neighborhood where  
60 B.1.526 was initially identified (2). Using these estimates and additional variant prevalence data,  
61 we further apply a city-level multi-variant, age-structured model to estimate the changes in  
62 transmissibility and immune escape potential for B.1.526. Lastly, we utilize findings from the  
63 first two model systems to estimate variant-specific infection fatality risk (IFR, i.e. the fraction  
64 of all persons with SARS-CoV-2 infection who died from the disease), for B.1.526 and B.1.1.7,  
65 separately. Overall, our study documents the emergence and impact of B.1.526. We close with a  
66 discussion on lessons learned from this SARS-CoV-2 VOI and implications for future COVID-  
67 19 pandemic response.

68

## 69 **RESULTS**

### 70 **Epidemic dynamics of the second pandemic wave in NYC**

71 NYC experienced a very large first pandemic wave during spring 2020. Similar to our previous  
72 work (6), the model-inference system here estimates that 16.6% of the population (95% CrI: 13.6  
73 – 21.5%; or 1.1 – 1.8 million people) had been infected by the end of May 2020 (i.e., end of the  
74 first wave; Fig 2D). The city was able to gradually reopen part of its economy during summer  
75 2020 after a 3-month long stay-at-home mandate for all non-essential workers. However,  
76 infection resurged beginning in the fall of 2020 and the city experienced a second pandemic

77 wave around Nov 2020 – April 2021 (Fig 2). Following the second wave, an estimated total of  
78 41.7% (95% CrI: 35.4 – 49.3%; or 3.0 – 4.1 million people) had been infected by the end of Apr  
79 2021, including all those infected during the first wave. Note these estimates accounted for  
80 under-detection of infections (Fig S1), for which the overall infection-detection rate increased to  
81 37.1% (95% CrI: 33.3 – 43.0%) during the 2<sup>nd</sup> wave from 15.1% (95% CrI: 11.7 – 18.5%) during  
82 the 1<sup>st</sup> wave. This large number of infections occurred despite the non-pharmaceutical  
83 interventions implemented throughout the pandemic and rollout of mass-vaccination starting  
84 mid-Dec 2020. In addition, unlike the first wave that predominantly affected older age groups,  
85 the second pandemic wave affected all age groups (Figs S2-3).

86

### 87 **Transmission rate increased earliest in the neighborhood where B.1.526 was initially** 88 **identified**

89 The emergence and rapid increase of B.1.526 coincided with the second pandemic wave in NYC.  
90 While first reported in Feb 2021 (2), testing initially identified the B.1.526 variant in patient  
91 samples dated back to early Nov 2020 from the city's WHts neighborhood (2). As such, we first  
92 examined potential changes in the transmission rate there. Indeed, prior to the identification of  
93 B.1.526, estimated neighborhood relative transmission rate ( $b_i$  in Eqn 1; see Methods) in WHts  
94 gradually increased, remained at high levels during Nov 2020 – Feb 2021, and decreased to the  
95 baseline level afterwards when B.1.526 became a predominant variant citywide (~40% of all  
96 cases sequenced by end of Feb 2021). In comparison, the estimates were relatively stable for  
97 other neighborhoods (Fig 3A), suggesting the changes in WHts were likely due to the early  
98 spread of B.1.526. Averaging over this period, we estimate that the relative transmission rate in  
99 WHts increased by 8.4% (95% CI: -5.8 – 22.5%). Concurrently, the citywide transmission rate  
100 increased by 13.3% (95% CI: -21.1 – 47.8%; Fig 3B). These two preliminary estimates in  
101 combination suggest that the transmission rate of B.1.526 likely is 22.8% (95% CI: -12.4 –  
102 58.0%) higher than preexisting non-VOC/VOI variants, without accounting for potential change  
103 due to immune evasion.

104

### 105 **B.1.526 likely causes a moderate increase in transmissibility (15-25%) and slight immune** 106 **evasion (0-10%)**

107 We further examine model estimations under a wide range of transmissibility and immune  
108 escape settings for B.1.526. Under all three possible scenarios of initial prevalence (i.e., 0.5 –  
109 2.5%, 1.5 – 3.5%, and 0.5 – 3.5%), model simulations consistently show that B.1.526 likely  
110 increases transmissibility by 15-30% and can escape immunity in 0-10% of previously infected  
111 persons (Fig 4 A-C). Overall, a higher initial prevalence (1.5 – 3.5% at the beginning of Nov  
112 2020) combining with a 15-25% increase in transmissibility and 0-10% immune escape (Fig 4 A-  
113 C, middle column; and Fig 4D) generated the most accurate estimates of cases, hospitalizations  
114 and deaths as well as variant percentages during the second wave. Model simulations show that,  
115 with this moderate increase in transmissibility and small immune escape, B.1.526 was able to  
116 outcompete preexisting variants and gradually increase its percentage from Nov 2020 to March

117 2021; however, afterwards its percentage decreased with the surge of B.1.1.7, a more infectious  
118 variant (Fig 4D, bottom right panel).

119

### 120 **B.1.526 likely increases disease severity substantially**

121 During the second wave, estimated IFR increased gradually in later months, particularly among  
122 older age groups (Fig 5). During this period (Nov 2020 – Apr 2021), 16-35% of hospital beds  
123 and 18-32% of intensive care unit (ICU) beds in NYC were available, suggesting lack of access  
124 to healthcare was not a reason behind the IFR increases. In addition, the number of COVID-19-  
125 related deaths declined following mass-vaccination in early 2021. Modeling accounting for  
126 infections and deaths due to B.1.526, B.1.1.7, and non-VOC/VOI variants suggests that B.1.526  
127 increased IFR in older adults: by 46% (95% CI: 7.4 – 84%) among 45-64 year-olds [absolute  
128 IFR: 0.42% (95% CI: 0.31 – 0.54%) vs. 0.29% (95% CI: 0.15 – 0.44%) baseline risk]; 82% (95%  
129 CI: 20 – 140%) among 65-74 year-olds [absolute IFR: 1.9% (95% CI: 1.2 – 2.5%) vs. 1.0%  
130 (95% CI: 0.57 – 2.5%) baseline risk], and 62% (95% CI: 45 – 80%) among 75+ [absolute IFR:  
131 6.7% (95% CI: 5.9 – 7.4%) vs. 4.1% (95% CI: 2.2 – 6.3%) baseline risk], during Nov 2020 –  
132 Apr 2021; overall, B.1.526 increased the IFR by 60% (95% CI: 38 – 82%), compared to  
133 estimated baseline risk (Table 1). The analysis restricting to Nov 2020 – Jan 2021 suggests  
134 similar IFR increases (Table S3). These estimated IFR increases were lower than for B.1.1.7 but  
135 comparable. Of note, the IFRs for B.1.1.7 estimated here were higher than but in line with those  
136 reported in the UK [e.g., overall increase: 100% (75-130%) vs. 61% (42–82%) in the UK(7)].

137

## 138 **DISCUSSION**

139 The B.1.526 variant is one of the SARS-CoV-2 variants designated as a VOI by both the WHO  
140 (1) and the US CDC (8). However, due to a lack of extensive genomic sequencing and contact  
141 tracing data particularly during the early phase of its emergence, its key epidemiological  
142 properties have not been well characterized. Utilizing multiple epidemiological datasets and  
143 comprehensive modeling, here we have estimated the changes in transmissibility, immune  
144 escape potential, and disease severity for B.1.526. Results suggest that, compared to preexisting  
145 non-VOC/VOI variants, B.1.526 causes a moderate increase in transmissibility and minimal  
146 immune evasion; however, it might substantially increase IFR in older adults. As such, continued  
147 monitoring of the circulation of this variant is warranted.

148

149 Our study offers several lessons for future outbreak response. First, prior to the emergence of  
150 B.1.526, the estimated transmission rate in WHts, where it likely emerged, was consistently  
151 higher than other neighborhoods in NYC throughout the pandemic. Population characteristics  
152 (e.g., household structure) that may contribute to this higher transmission rate need further  
153 investigation; however, the higher transmission rate may have facilitated the spread of new  
154 mutants between hosts and its emergence population-wide. It is thus important to closely monitor  
155 populations with sustained higher transmission rates for new variants, particularly in areas

156 lacking robust and timely sequencing of samples from newly identified cases. In addition, the  
157 estimated transmission rate in WHts further increased in conjunction with the emergence of  
158 B.1.526; such changes thus may serve as an early indicator for in-depth epidemiological  
159 investigation (e.g., to assess changes in circulating variants and transmissibility). A similar  
160 approach has been applied in the UK, where subregions with higher estimated growth rates were  
161 prospectively investigated, leading to identification of B.1.1.7 as a VOC (9-12).

162  
163 Second, we did not find a higher B.1.526-related IFR among younger age groups (those under 45  
164 years); this finding is consistent with the findings of Thompson et al. (4) based on analysis of all  
165 sequenced cases, the majority of whom (67%) were under 45 years. However, for older ages, we  
166 found substantially higher B.1.526-related IFRs (e.g. >60% higher for those above 65 years).  
167 This latter finding appears to be consistent with the report by Annavajhala et al. (2) showing  
168 resistance of B.1.526 to therapeutic antibodies. Over the course of the pandemic, SARS-CoV-2  
169 IFR has decreased substantially (about a 3-fold difference between the two pandemic waves),  
170 likely due to improved medical treatments (e.g., therapeutic antibodies), better patient  
171 management, and earlier diagnosis. As older adults are more likely to suffer from severe  
172 COVID-19 and thus receive therapeutic antibodies (13, 14), the resistance of B.1.526 may render  
173 these treatments ineffective despite their prior success against other variants, leading to increases  
174 in IFR among older adults. These findings highlight the importance of monitoring the efficacy of  
175 therapeutics against different variants and timely update of treatments. In addition, a better  
176 understanding of factors contributing to the higher IFRs in certain variants is warranted to inform  
177 countermeasures (15, 16).

178  
179 Lastly, our analyses suggest both B.1.526 and B.1.1.7 likely had been spreading in the  
180 population for weeks or months prior to detection by the surveillance system (2, 3, 17).  
181 Expanding genomic sequencing programs for SARS-CoV-2 and improving linkage to  
182 epidemiologic data can improve detection of new VOIs/VOCs. Such efforts are underway (e.g.,  
183 in the US) but more efforts and resources are urgently needed globally. In addition, to support  
184 more timely detection and control, targeted screening of key subpopulations (e.g., those  
185 prospectively identified from modeling as having high transmission rates) and viral traits (e.g.,  
186 mutations linked to increased transmissibility and/or immune evasion as done in Annavajhala et  
187 al.(2)) is needed, as well as timely sharing of key information globally. The documentation of  
188 new VOIs/VOCs anywhere in the world then should prompt preparedness measures to detect and  
189 rapidly respond to the introduction of those variants into local areas. More fundamentally, to  
190 limit emergence of new VOIs/VOCs and end the COVID-19 pandemic, all populations  
191 worldwide should have timely access to vaccination, and multiple layers of mitigation efforts are  
192 needed until a sufficient portion of the population is protected by vaccination.

193  
194 Our study also has several limitations. First, most of our analyses are based on population-level  
195 data without variant-specific information, given limited variant testing during most of the study

196 period. We circumvented this data deficiency by analyzing estimates of a key subpopulation  
197 (e.g., the WHts neighborhood where B.1.526 was initially detected) and leveraging prior  
198 knowledge (e.g., estimated IFR prior to B.1.526 emergence). Second, our study did not  
199 distinguish the two subclades within the B.1.526 lineage – one containing the E484K mutation  
200 and the other containing the S477N mutation. Both the E484K and S477N mutations have been  
201 shown to mediate immune escape (16, 18-20); in addition, the percentages of these two  
202 subclades were similar during our study period, suggesting they likely have similar  
203 epidemiological characteristics. Third, while it is likely that the emergence of B.1.526 led to the  
204 increase in transmission rate in WHts at the time, we cannot rule out the possibility that other  
205 factors contributed to this increase and in turn the emergence of B.1.526. Lastly, there is a likely  
206 larger uncertainty in B.1.526-related and B.1.1.7-related IFR estimates for younger ages (those  
207 under 45), due to the smaller number of deaths and larger uncertainty in baseline IFR estimates.  
208 Future investigation addressing these issues is warranted should a large sample of variant-  
209 specific data become available.

210  
211 In summary, our study has reconstructed the early epidemic trajectory and subsequent rise of  
212 B.1.526 in NYC and estimated its key epidemiological properties. Findings highlight the  
213 importance of monitoring the viral diversity of SARS-CoV-2, epidemiological characteristics of  
214 new variants, and disease severity, as COVID-19 remains a global public health threat.

215

## 216 **MATERIALS AND METHODS**

### 217 **Study design and data**

218 This study included three interconnected modeling analyses, synthesizing nine epidemiological  
219 and population datasets (Fig 1). The first analysis applied a network model-inference system to  
220 reconstruct underlying SARS-CoV-2 transmission dynamics in NYC, accounting for under-  
221 detection of infection; it also enabled estimation of key population variables and parameters  
222 (e.g., the infection rate including those not detected as cases and transmission rate). The second  
223 analysis applied a city-level multi-variant, age-structured model to simulate and estimate the  
224 changes in transmissibility and immune escape potential for B.1.526 based on the network  
225 model-inference estimates and additional data (e.g., variant prevalence data). The last analysis  
226 utilized estimates from the first two model systems to estimate variant-specific infection fatality  
227 risk (IFR, i.e. the fraction of all persons with SARS-CoV-2 infection who died from the disease),  
228 for B.1.526 and B.1.1.7, separately.

229

230 For the network model-inference system, we utilized multiple sources of epidemiological data,  
231 including confirmed and probable COVID-19 cases, emergency department (ED) visits, and  
232 deaths, as well as vaccination data. As done previously (6), we aggregated all COVID-19  
233 confirmed and probable cases (21, 22) and deaths (22) reported to the NYC Department of  
234 Health and Mental Hygiene (DOHMH) by age group (<1, 1-4, 5-14, 15-24, 25-44, 45-64, 65-74,

235 and 75+ year-olds), neighborhood of residence (42 United Hospital Fund neighborhoods in  
236 NYC(23)) and week of occurrence (i.e., week of diagnosis for cases or week of death for  
237 decedents). COVID-19-related ED visit data were obtained from the NYC syndromic  
238 surveillance system, comprised of all 53 hospital EDs in the city (24). This system identified  
239 individuals presenting at the EDs with COVID-like-illness (CLI; defined as having a fever and  
240 cough or sore throat or respiratory illness, or pneumonia, or a COVID-19 discharge diagnosis  
241 code, excluding those with a discharge diagnosis code of influenza only); in addition, CLI  
242 patients were matched to electronic laboratory reports of SARS-CoV-2 tests with diagnosis  
243 date within  $\pm 7$  days of ED visit. We estimated the number of COVID-19-related ED visits as the  
244 number classified as CLI multiplied by the percentage of those who tested positive for SARS-  
245 CoV-2 RNA, stratified by the same age and neighborhood groups in weekly intervals. To  
246 account for the impact of vaccination, we also included COVID-19 vaccination data (partially  
247 and fully vaccinated, separately), aggregated to the same age/neighborhood strata by week.

248  
249 In addition, as in our previous study (6), we used mobility data from SafeGraph (25) to model  
250 changes in SARS-CoV-2 transmission rate due to non-pharmaceutical interventions. These data  
251 were aggregated to the neighborhood level by week without age stratification.

252  
253 For the multi-variant model analysis, we additionally utilized four city-level, weekly datasets: 1)  
254 COVID-19 confirmed and probable cases, 2) hospitalizations (26), 3) deaths, and 4) the  
255 percentage of different variants in NYC based on genomic sequencing of samples submitted to  
256 the NYC DOHMH Public Health Laboratory and Pandemic Response Laboratory (4, 27). The  
257 additional hospitalization and variant percentage data were published by the NYC DOHMH (26,  
258 27) and accessed on June 22, 2021. We used the variant data from the week starting Jan 31, 2021  
259 to the week starting April 25, 2021 in this analysis, because earlier weeks had very low sample  
260 sizes (<200 samples sequenced per week).

261  
262 This study was classified as public health surveillance and exempt from ethical review and  
263 informed consent by the Institutional Review Boards of both Columbia University and NYC  
264 DOHMH.

### 265 266 **Network model-inference system**

267 The network model-inference system used here is similar to the approach described in Yang et  
268 al.(6); however, here we further accounted for waning immunity and vaccination and  
269 additionally used COVID-19-related ED visit data for model optimization. Briefly, the model-  
270 inference system uses an epidemic model (Eqn 1) to simulate the transmission of SARS-CoV-2  
271 by age group and neighborhood, under implemented public health interventions and mass-  
272 vaccination when vaccines became available starting Dec 14, 2020:

273

$$\left\{ \begin{array}{l} \frac{dS_i}{dt} = \frac{R_i}{L} - \left( S_i \sum_{j=1}^{j=42} \frac{b_s b_j \beta_{city} m_{ij} I_j}{N_j} \right) - v_{i,1} - v_{i,2} \\ \frac{dE_i}{dt} = \left( S_i \sum_{j=1}^{j=42} \frac{b_s b_j \beta_{city} m_{ij} I_j}{N_j} \right) - \frac{E_i}{Z} \\ \frac{dI_i}{dt} = \frac{E_i}{Z} - \frac{I_i}{D} \\ \frac{dR_i}{dt} = \frac{I_i}{D} - \frac{R_i}{L} + v_{i,1} + v_{i,2} \end{array} \right. \quad [1]$$

274  
 275 where  $S_i$ ,  $E_i$ ,  $I_i$ ,  $R_i$ , and  $N_i$  are the number of susceptible, exposed (but not yet infectious),  
 276 infectious, and removed (either recovered, immune, or deceased) individuals and the total  
 277 population, respectively, from a given age group in neighborhood- $i$ .  $\beta_{city}$  is the average citywide  
 278 transmission rate;  $b_s$  is the estimated seasonal trend (6). The term  $b_i$  represents the neighborhood-  
 279 level transmission rate relative to the city average. The term  $m_{ij}$  represents the changes in contact  
 280 rate in each neighborhood (for  $i=j$ ) or spatial transmission from neighborhood- $j$  to  $i$  (for  $i \neq j$ ) and  
 281 was computed based on the mobility data (6).  $Z$ ,  $D$ , and  $L$  are the latency period, infectious  
 282 period, and immunity period, respectively. The term  $v_{i,1}$  represents the number of individuals in  
 283 neighborhood- $i$  successfully immunized after the first dose of the vaccine and is computed using  
 284 vaccination data and vaccine efficacy (VE) for 1<sup>st</sup> dose;  $v_{i,2}$  is the additional number of  
 285 individuals successfully immunized after the second vaccine dose (excluding those successfully  
 286 immunized after the first dose). Because 97% of vaccine doses administered in NYC during our  
 287 study period (through April 30, 2021) were the Pfizer-BioNTech or Moderna vaccines, we  
 288 assumed a VE of 85% fourteen days after the first dose and 95% seven days after the second  
 289 dose based on clinical trials and real-world data (28-30).

290  
 291 Using the model-simulated number of infections occurring each day, we further computed the  
 292 number of cases, ED visits, and deaths each week to match with the observations (6). Similar to  
 293 the procedure for cases and deaths described in Yang et al.(6), to compute the number of ED  
 294 visits, we multiplied the model-simulated number of new infections per day by the ED-  
 295 consultation rate (i.e. the fraction of model-simulated persons with new SARS-CoV-2 infections  
 296 presenting at the EDs), and further distribute these estimates in time per a distribution of time-  
 297 from-infection-to-ED-consultation (Table S1); we then aggregated the daily lagged, simulated  
 298 estimates to weekly totals for model inference.

299  
 300 Each week, the system uses the ensemble adjustment Kalman filter (EAKF)(31) to compute the  
 301 posterior estimates of model state variables and parameters based on the model (prior) estimates  
 302 and observed case, ED visit, and mortality data per Bayes' rule (6). In particular, using this  
 303 model-inference, we estimated the citywide transmission rate ( $\beta_{city}$ ), neighborhood relative  
 304 transmission rate ( $b_i$ ), and IFR by age group for each week, from the week starting March 1,



305 2020 (i.e. the beginning of the COVID-19 pandemic in NYC) to the week starting April 25,  
 306 2021.

307

308 **Multi-variant, age-structured model**

309 Due to model complexity, the model-inference system described above does not account for the  
 310 circulation of different variants. To model variants, we used a city-level multi-variant, age-  
 311 structured model (32), per Eqn 2:

312

$$\left\{ \begin{array}{l} \frac{dS_i^A}{dt} = \frac{R_i^A}{L_i^A} - \sum_j b_s m c_{ij} \sum_a \frac{\beta_j^{Aa} S_j^A I_j^a}{N^a} - \varepsilon_i - v_{i,1}^A - v_{i,2}^A \\ \frac{dE_i^A}{dt} = b_s m \sum_a \frac{\beta_i^{Aa} S_i^A I_i^a}{N^a} - \frac{E_i^A}{Z_i^A} + \varepsilon_i \\ \frac{dI_i^A}{dt} = \frac{E_i^A}{Z_i^A} - \frac{I_i^A}{D_i^A} \\ \frac{dR_i^A}{dt} = \frac{I_i^A}{D_i^A} - \frac{R_i^A}{L_i^A} + v_{i,1}^A + v_{i,2}^A \end{array} \right. \quad [2]$$

313

314 Model variables and parameters in Eqn 2 are similar to those in Eqn 1 with the same symbols.  
 315 For instance,  $\beta_i$  is the transmission rate for variant- $i$ . However, instead of modeling the spatial  
 316 structure, Eqn 2 focuses on the interactions among different variants (indicated by the subscript,  
 317  $i$ ) and age structure (indicated by the superscript,  $a$  or  $A$ ). For age structure, infection in age  
 318 group  $A$  by variant- $i$  comes from all age groups, per the summation  $b_s m \sum_a \frac{\beta_i^{Aa} S_i^A I_i^a}{N^a}$  (see the 2<sup>nd</sup>  
 319 line in Eqn 2). For variant interactions via cross-immunity, we use a status-based construct  
 320 similar to Yang et al. (33) and Gog and Grenfell (34). Specifically,  $c_{ij}$  measures the strength of  
 321 cross-immunity to variant- $i$  conferred by infection of variant- $j$  (e.g., close to 0 if it is weak and  
 322  $c_{ii}=1$  for infection by the same variant). To compute the depletion of susceptibility to variant- $i$   
 323 due to infection of variant- $j$  ( $i \neq j$ ), we multiply that infection by  $c_{ij}$ ; that is, non-specific immunity  
 324 is scaled by the strength of cross-immunity  $c_{ij}$ . As such, the double summation

325  $\sum_j b_s m c_{ij} \sum_a \frac{\beta_j^{Aa} S_j^A I_j^a}{N^a}$  in Line 1 of Eqn 2 represents the depletion of susceptibility due to variant-  
 326 specific infection (when  $i=j$ ) and non-specific infections (for all  $i \neq j$ ). The vaccination model  
 327 component  $v_{i,1}^A$  and  $v_{i,2}^A$  are also variant-specific and can additionally account for the reduction in  
 328 VE against the new variants if needed; however, here we used the same VE estimates for all  
 329 variants included (i.e., B.1.526, B.1.1.7, B.1.427 and B.1.429) based on observations (4, 30, 35,  
 330 36). Additionally, the term  $\varepsilon_i$  represents travel-related importation of infections of variant- $i$  (see  
 331 Table S2).

332

333 We restricted this simulation to Nov 2020 – Apr 2021 (i.e., from the initial identification of  
 334 B.1.526 to before the further detection and increase of other variants such as Gamma and Delta).  
 335 In addition to preexisting variants of SARS-CoV-2 prior to Nov 2020 (i.e. “non-VOC/VOI  
 336 variants” for simplicity) and B.1.526, the model included B.1.1.7 and B.1.427/B.1.429  
 337 (combined for simplicity), based on available genomic surveillance data showing consistent  
 338 detection of these variants during the simulation period and very low levels for others if detected.

339 Model parameters for B.1.1.7 and B.1.427/B.1.429 were listed in Table S2. For simplicity, we  
340 did not account for other VOCs/VOIs variants because their percentages were very low during  
341 either analysis period (27).

342  
343 Initial analysis based on the model-inference estimates suggested B.1.526 was around 20% more  
344 infectious than non-VOC/VOI variants, without accounting for changes in immunity due to  
345 potential immune escape (see details in Results). Therefore, in this analysis, we tested  
346 combinations of change in transmissibility ranging from 10 – 30% increases and immune escape  
347 ranging from 0 – 30%, both with a 5% increment and  $\pm 5\%$  intervals (35 combinations in total).  
348 For instance, for the combination centering at 10% transmissibility increase and 0% immune  
349 escape, the model is initialized using values in the range of 5-15% (i.e.,  $10 \pm 5\%$ ) transmissibility  
350 increase and 0-5% (i.e.,  $0 \pm 5\%$  and setting negatives to 0) immune escape. In addition, due to  
351 uncertainty on the initial prevalence, we tested three different levels of initial seeding for the  
352 week starting Nov 1, 2020, i.e., low (0.5 – 2.5%), high (1.5 – 3.5%), and wider range (0.5 –  
353 3.5%). For reference, Washington Heights – Inwood (WHts), which is the neighborhood where  
354 the first patients identified with B.1.526 resided and sought care, constituted 3.2% of the NYC  
355 population in 2018. We initialized the model using the model-inference estimates (e.g.,  
356 population susceptibility and transmission rates by age group; Table S2) and ran the model for  
357 each parameter combination 10 times, each with 1000 realizations to account for model  
358 stochasticity. Results are summarized from the 10,000 model realizations.

359  
360 To identify the most plausible combination of transmissibility and immune escape properties for  
361 B.1.526, we compared the model-estimated weekly number of cases, hospitalization, and deaths  
362 as well as the percentage of the variants to available data. Evaluation was made based on 1)  
363 accuracy, i.e., if the observation falls within the model-estimated interquartile range, it is deemed  
364 accurate; 2) relative root-mean-square-error (RMSE) between the observed and the model-  
365 estimated; and 3) Pearson correlation between the two time-series. Because results show that  
366 model accuracy and relative RMSE had a wider spread among the combinations tested (i.e.,  
367 more distinctive), we first subset those having accuracy within the highest 25<sup>th</sup> percentile and  
368 relative RMSE within the lowest 25<sup>th</sup> percentile (2-4 out of 35 combinations remained for each  
369 setting of initial prevalence); we then selected the one with the highest correlation in the subset  
370 as the best-performing and most plausible combination.

371

### 372 **Estimating the changes in IFR due to B.1.526**

373 The network model-inference system enables estimation of the IFR by age group over time.  
374 These estimates are made combining all variants and do not distinguish by variant. However, we  
375 reasoned that the combined IFR is a weighted average of individual, variant-specific estimates  
376 given the relative prevalence of each variant. Accordingly, we built two linear regression models  
377 to estimate the variant-specific IFR. Model 1 restricted the analysis to Nov 2020 – Jan 2021

378 (when the relative prevalence of B.1.1.7 in NYC was likely <10%; n = 14 weeks) and only  
379 included two categories of variants:

$$IFR_{combined} \sim IFR_{B.1.526} i_{B.1.526} + IFR_{baseline} i_{others} \quad [3]$$

380

381 Model 2 extended the analysis to Nov 2020 – Apr 2021 (n = 26 weeks) and included both  
382 B.1.526 and B.1.1.7, in addition to other variants:

$$IFR_{combined} \sim IFR_{B.1.526} i_{B.1.526} + IFR_{B.1.1.7} i_{B.1.1.7} + IFR_{baseline} i_{others} \quad [4]$$

383

384 In both models,  $IFR_{combined}$  is the overall IFR for each week, estimated using the model-inference  
385 system;  $i_{B.1.526}$ ,  $i_{B.1.1.7}$ ,  $i_{others}$  are the percentage of infection by the corresponding variant for each  
386 week, estimated using the multi-variant age-structured model with the most plausible parameter  
387 combination as data are not available.  $IFR_{baseline}$  is the baseline IFR for the preexisting variants,  
388 set to the average of model-inference estimates over the period of Oct – Nov 2020 (i.e., prior to  
389 the increase of the new variants). The variant-specific IFRs,  $IFR_{B.1.526}$  and  $IFR_{B.1.1.7}$ , are then  
390 estimated using the regression models (n = 14 weekly data points for Model 1; and n = 26  
391 weekly data points for Model 2). For either model, the change in IFR due to a given variant is  
392 then computed as:

$$\Delta IFR = \frac{IFR_{variant} - IFR_{baseline}}{IFR_{baseline}} \times 100\% \quad [5]$$

393

394 Both model analyses were performed for each age group or all ages combined, separately; we  
395 also combined all those aged under 25 as the IFRs were similarly low for the four sub-age groups  
396 (i.e. <1, 1-4, 5-14, and 15-24 year-olds).

397

## 398 **Supplementary Materials**

399 **Table S1.** Prior ranges for the network model-inference system. The prior ranges are similar to  
400 Table S1 of Yang et al.(6) but include additional parameters in Eqn 1. The spatial, temporal, and  
401 age resolution of each parameter or variable, estimated in the model-inference system, is  
402 specified in the column "Resolution". Note posterior parameter estimates can extend outside the  
403 specified prior ranges.

404

405 **Table S2.** Initial conditions used to simulate co-circulation of different variants in the multi-  
406 variant, age-structured model. To partially account for changing infection-detection rate, ED-  
407 consultation rate (EDR) and IFR, for these three parameters, we used the model-inference  
408 estimates averaged over the entire simulation period (i.e. Nov 2020 – April 2021). For the initial  
409 transmission rate (for the preexisting non-VOC/VOI variants), we used the model-inference  
410 estimates averaged over the week of 10/25/2020 – the week of 11/7/2020 (i.e. the 3 weeks  
411 around the start of simulation). For the rest of model state variables and parameters, we used  
412 model-inference estimates made at the week of 10/25/2020. For B.1.1.7, we used the following

413 ranges based on estimates from Yang and Shaman (32): 40.3 – 52.3% higher transmissibility  
414 (related to estimates for the preexisting non-VOC/VOI variants listed below) and 0 – 10%  
415 immune escape; for comparison, contact tracing data from the UK showed that B.1.1.7 was 30-  
416 50% more infectious (37). For B.1.427/ B.1.429, we used the following ranges based on  
417 estimates from Deng et al.(38): 16 – 24% higher transmissibility and 0-10% immune escape (vs.  
418 21.4 – 27.8% increase in transmission rate in Deng et al.(38) without accounting for changes in  
419 immunity due to potential immune escape).

420

421 **Table S3.** Estimated IFR for different variants and changes compared to the baseline risk  
422 estimated for preexisting variants during Oct – Dec 2020, using Eqn 3.

423

424 **Fig S1.** Estimated infection-detection rate by age group. Red lines show the estimated median  
425 infection-detection rate with surrounding areas indicating the 50% (darker color) and 95%  
426 (lighter color) CrI. For comparison, the grey bars show the number of cases reported for each  
427 week from the week of Oct 4, 2020 to Apr 25, 2021. Labels of x-axis show the week starts  
428 (mm/dd/yy).

429

430 **Fig S2.** Model-fit by age group. Boxes show model estimates (thick horizontal lines and box  
431 edges show the median, 25<sup>th</sup>, and 75<sup>th</sup> percentiles; vertical lines extending from each box show  
432 95% CrI) and red dots show corresponding.

433

434 **Fig S3.** Estimated cumulative infection rates by age group. Thick horizontal lines and box edges  
435 show the median, 25<sup>th</sup>, and 75<sup>th</sup> percentiles; vertical lines extending from each box show 95%  
436 CrI.

437

## 438 **References and Notes**

- 439 1. World Health Organization, Tracking SARS-CoV-2 variants, 2021,  
440 <https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/>
- 441 2. M. K. Annavajhala *et al.*, A Novel and Expanding SARS-CoV-2 Variant, B.1.526,  
442 Identified in New York. *medRxiv*, 2021.2002.2023.21252259 (2021).
- 443 3. A. P. West *et al.*, Detection and characterization of the SARS-CoV-2 lineage B.1.526 in  
444 New York. *bioRxiv*, 2021.2002.2014.431043 (2021).
- 445 4. C. N. Thompson *et al.*, Rapid Emergence and Epidemiologic Characteristics of the  
446 SARS-CoV-2 B.1.526 Variant - New York City, New York, January 1-April 5, 2021.  
447 *MMWR. Morbidity and mortality weekly report* **70**, 712-716 (2021).
- 448 5. Global Initiative on Sharing All Influenza Data (GISAI), GISAI, 2021,  
449 <https://www.gisaid.org>
- 450 6. W. Yang *et al.*, Estimating the infection-fatality risk of SARS-CoV-2 in New York City  
451 during the spring 2020 pandemic wave: a model-based analysis. *The Lancet. Infectious*  
452 *diseases* **21**, 203-212 (2021).

- 453 7. N. G. Davies *et al.*, Increased mortality in community-tested cases of SARS-CoV-2  
454 lineage B.1.1.7. *Nature* **593**, 270-274 (2021).
- 455 8. Centers for Disease Control and Prevention, SARS-CoV-2 Variant Classifications and  
456 Definitions, 2021, <https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html>
- 457 9. New and Emerging Respiratory Virus Threats Advisory Group, "Minutes of the  
458 NERVTAG COVID-19 Fortieth Meeting: 11 December 2020," (2020).
- 459 10. New and Emerging Respiratory Virus Threats Advisory Group, "Minutes of the  
460 extraordinary meeting of NERVTAG COVID-19 and SPI-M on SARS-CoV-2 variants:  
461 21 December 2020," (2020).
- 462 11. New and Emerging Respiratory Virus Threats Advisory Group, "NERVTAG/SPI-M  
463 Extraordinary meeting on SARS-CoV-2 variant of concern 202012/01 (variant B.1.1.7),"  
464 (2020).
- 465 12. E. Volz *et al.*, Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from  
466 linking epidemiological and genetic data. *medRxiv*, 2020.2012.2030.20249034 (2021).
- 467 13. National Institutes of Health, COVID-19 Treatment Guidelines: Anti-SARS-CoV-2  
468 Monoclonal Antibodies, 2021,  
469 [https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-](https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-products/anti-sars-cov-2-monoclonal-antibodies/)  
470 [products/anti-sars-cov-2-monoclonal-antibodies/](https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-products/anti-sars-cov-2-monoclonal-antibodies/)
- 471 14. Centers for Disease Control and Prevention, COVID-19: Treatment considerations for  
472 healthcare providers, 2021, [https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-](https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html)  
473 [info.html](https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html)
- 474 15. T. N. Starr *et al.*, Prospective mapping of viral mutations that escape antibodies used to  
475 treat COVID-19. *Science* **371**, 850-+ (2021).
- 476 16. A. J. Greaney *et al.*, Complete Mapping of Mutations to the SARS-CoV-2 Spike  
477 Receptor-Binding Domain that Escape Antibody Recognition. *Cell Host & Microbe* **29**,  
478 44-57.e49 (2021).
- 479 17. N. L. Washington *et al.*, Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in  
480 the United States. *Cell* **184**, 2587-+ (2021).
- 481 18. A. J. Greaney *et al.*, Comprehensive mapping of mutations in the SARS-CoV-2 receptor-  
482 binding domain that affect recognition by polyclonal human plasma antibodies. *Cell Host*  
483 *& Microbe* **29**, 463-476.e466 (2021).
- 484 19. Z. Liu *et al.*, Identification of SARS-CoV-2 spike mutations that attenuate monoclonal  
485 and serum antibody neutralization. *Cell host & microbe* **29**, 477-488.e474 (2021).
- 486 20. W. T. Harvey *et al.*, SARS-CoV-2 variants, spike mutations and immune escape. *Nature*  
487 *Reviews Microbiology* **19**, 409-424 (2021).
- 488 21. Centers for Disease Control and Prevention, National Notifiable Diseases Surveillance  
489 System (NNDSS) - Coronavirus Disease 2019 (COVID-19), 2021,  
490 <https://ndc.services.cdc.gov/conditions/coronavirus-disease-2019-covid-19/>
- 491 22. New York City Department of Health and Mental Hygiene, Defining confirmed and  
492 probable cases and deaths, 2020, [https://www1.nyc.gov/site/doh/covid/covid-19-](https://www1.nyc.gov/site/doh/covid/covid-19-data.page)  
493 [data.page](https://www1.nyc.gov/site/doh/covid/covid-19-data.page)
- 494 23. New York City Department of Health and Mental Hygiene, NYC UHF 42  
495 Neighborhoods, <http://a816-dohbesp.nyc.gov/IndicatorPublic/EPHTPDF/uhf42.pdf>
- 496 24. R. Lall *et al.*, Advancing the Use of Emergency Department Syndromic Surveillance  
497 Data, New York City, 2012-2016. *Public Health Rep* **132**, 23s-30s (2017).

- 498 25. SafeGraph, Weekly Patterns: Foot Traffic Data To Understand The COVID-19  
499 Pandemic, 2020, <https://www.safegraph.com/weekly-foot-traffic-patterns>
- 500 26. New York City Department of Health and Mental Hygiene, NYC Coronavirus Disease  
501 2019 (COVID-19) Data, <https://github.com/nychealth/coronavirus-data>
- 502 27. New York City Department of Health and Mental Hygiene, Variants, 2021,  
503 <https://github.com/nychealth/coronavirus-data/tree/master/variants>
- 504 28. F. P. Polack *et al.*, Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *New*  
505 *Engl J Med*, (2020).
- 506 29. L. R. Baden *et al.*, Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N*  
507 *Engl J Med* **384**, 403-416 (2021).
- 508 30. E. J. Haas *et al.*, Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-  
509 CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a  
510 nationwide vaccination campaign in Israel: an observational study using national  
511 surveillance data. *The Lancet* **397**, 1819-1829 (2021).
- 512 31. J. L. Anderson, An ensemble adjustment Kalman filter for data assimilation. *Mon.*  
513 *Weather Rev.* **129**, 2884-2903 (2001).
- 514 32. W. Yang, J. Shaman, Development of a model-inference system for estimating  
515 epidemiological characteristics of SARS-CoV-2 variants of concern. *Nature*  
516 *Communications* **12**, 5573 (2021).
- 517 33. W. Yang, E. H. Y. Lau, B. J. Cowling, Dynamic interactions of influenza viruses in Hong  
518 Kong during 1998-2018. *PLoS Comput Biol* **16**, e1007989 (2020).
- 519 34. J. R. Gog, B. T. Grenfell, Dynamics and selection of many-strain pathogens. *Proc Natl*  
520 *Acad Sci U S A* **99**, 17209-17214 (2002).
- 521 35. L. J. Abu-Raddad, H. Chemaitelly, A. A. Butt, C.-V. National Study Group for,  
522 Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351  
523 Variants. *N Engl J Med* **385**, 187-189 (2021).
- 524 36. W. F. Garcia-Beltran *et al.*, Multiple SARS-CoV-2 variants escape neutralization by  
525 vaccine-induced humoral immunity. *Cell* **184**, 2372-2383 e2379 (2021).
- 526 37. Public Health England, "Investigation of novel SARS-CoV-2 variant, Variant of Concern  
527 202012/01, Technical briefing 3," (2020).
- 528 38. X. Deng *et al.*, Transmission, infectivity, and antibody neutralization of an emerging  
529 SARS-CoV-2 variant in California carrying a L452R spike protein mutation. *medRxiv*,  
530 2021.2003.2007.21252647 (2021).
- 531 39. W. Yang, wan-yang/covid\_voc\_study: covid\_voc\_study\_yang\_shaman\_2021\_NatComm  
532 (v1.0). Zenodo., 2021, <https://doi.org/10.5281/zenodo.5715611>
- 533 40. New York City Department of Health and Mental Hygiene.
- 534 41. J. Mossong *et al.*, Social contacts and mixing patterns relevant to the spread of infectious  
535 diseases. *PLoS Med* **5**, e74 (2008).
- 536 42. Q. Li *et al.*, Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-  
537 Infected Pneumonia. *New Engl J Med*, (2020).
- 538 43. J. T. Wu, K. Leung, G. M. Leung, Nowcasting and forecasting the potential domestic and  
539 international spread of the 2019-nCoV outbreak originating in Wuhan, China: a  
540 modelling study. *Lancet* **395**, 689-697 (2020).
- 541 44. R. Li *et al.*, Substantial undocumented infection facilitates the rapid dissemination of  
542 novel coronavirus (SARS-CoV-2). *Science* **368**, 489-493 (2020).

- 543 45. J. Zhang *et al.*, Evolving epidemiology and transmission dynamics of coronavirus disease  
544 2019 outside Hubei province, China: a descriptive and modelling study. *The Lancet.*  
545 *Infectious diseases* **20**, 793-802 (2020).  
546 46. W. Yang, J. Shaman, A simple modification for improving inference of non-linear  
547 dynamical systems. *arXiv*, 1403.6804 (2014).  
548 47. R. Verity *et al.*, Estimates of the severity of coronavirus disease 2019: a model-based  
549 analysis. *The Lancet. Infectious diseases* **20**, 669-677 (2020).  
550

**Acknowledgments:** We thank Columbia University Mailman School of Public Health for high performance computing, Safe Graph ([safegraph.com](https://safegraph.com)) for providing the mobility data, and Sasikiran Kandula at Columbia University for compiling the mobility data used in this study. We thank the NYC DOHMH Incident Command System Surveillance and Epidemiology Section for processing, cleaning, and managing COVID-19 surveillance data, the NYC DOHMH Public Health Laboratory and Pandemic Response Laboratory for generating and analyzing sequence data, and Iris Cheng, Mohammed Almashhadani, Charles Ko, and Jaimie Shaff from the NYC DOHMH for providing the vaccination data and helpful suggestions on the manuscript.

**Funding:** This study was supported by the National Institute of Allergy and Infectious Diseases (AI145883) and the NYC DOHMH.

**Author contributions:** WY designed the study, conducted the analysis, and wrote the first draft; SKG contributed to study coordination and specification of COVID-19 case data, and provided input on parameter estimation; ERP led aggregation and provision of COVID-19 case data; LG contributed to management of COVID-19 case data; WL provided the COVID-19-associated mortality data; RM and RL oversaw the collection of and provided the COVID-19 ED data; SH and JW provided input on SARS-CoV-2 variants and interpretation of the NYC variant percentage data; AF oversaw data collection and management processes at DOHMH. All authors contributed to the final draft.

**Competing interests:** Authors declare that they have no competing interests.

**Data and materials availability:** The COVID-19 case and mortality data were used with permission under a Data Use and Nondisclosure Agreement between the New York City Department of Health and Mental Hygiene and Columbia University. The New York City Department of Health and Mental Hygiene also has a comprehensive, publicly available data website here: <https://github.com/nychealth/coronavirus-data>. Additional data sources are detailed in the manuscript. Model code for the multi-variant, age-structured model and a simpler

model-inference system using the ensemble adjustment Kalman filter (EAKF; see ref (32)) is available on Zenodo (39).

## Figures

**Fig 1.** Study design. This study included three modeling analyses: 1) spatial network model-inference to construct the transmission dynamics and estimate key population variables and parameters by United Hospital Fund (UHF) neighborhood of residence and age group; 2) city-level multi-variant, age-structured modeling to simulate and estimate the changes in transmissibility and immune escape potential for B.1.526; and 3) linear regression models to estimate variant-specific infection fatality risk (IFR), for B.1.526 and B.1.1.7, separately. Nine datasets (listed in the black open boxes) were used as model inputs or to evaluate the accuracy of model estimates (indicated for each dataset below). Models used are shown in the blue filled boxes and model outputs are listed in the blue open boxes (key estimates reported in detail in the Results are bolded). Connections among the analyses are indicated by the arrows and associated annotations.

**Fig 2.** Model fit and key estimates. Upper panel shows model-fit to weekly number of cases (A), ED visits (B), and deaths (C), for all ages combined. Lower panel shows key model-inference estimates of weekly number of infections including those not detected as cases (D), cumulative number of infections in NYC overall (E), and cumulative infection rate by neighborhood (F). Boxes show model estimates (thick horizontal lines and box edges show the median, 25<sup>th</sup>, and 75<sup>th</sup> percentiles; vertical lines extending from each box show 95% CrI) and red dots show corresponding. For the weekly estimates, week starts (mm/dd/yy) are shown in the x-axis labels. Star (\*) in the map indicates the location of the Washington Heights – Inwood neighborhood.

**Fig 3.** Changes in transmission rate. (A) Changes in neighborhood-level relative transmission rate. (B) Changes in citywide transmission rate. Vertical dashed lines indicate the earliest date B.1.526 was identified as reported in Annavajhala et al. Labels of x-axis show the week starts (mm/dd/yy).

**Fig 4.** Comparison of different combinations of changes in transmissibility and immune escape property for B.1.526. Left panel shows the overall accuracy (A), relative RMSE (B), and correlation (C) of model estimates under different transmissibility and immune escape settings. White crosses (x) indicate the best-performing parameter combination. Right panel shows model estimates using the overall best-performing parameter combination (i.e., 1.5-3.5% initial prevalence, 15-25% higher transmissibility, and 0-10% immune escape). Lines and surrounding areas show model-simulated median estimates and interquartile range; dots show corresponding observations; colors indicate different variants as specified in the legend. Note that these model simulations used same infection-detection rate, hospitalization-rate and IFR (i.e., average during Nov 2020 – Apr 2021); that is, they did not account for changes in case ascertainment or disease



severity by week during this period, due to, e.g., increases in disease severity by the new variants. As such, there were larger deviations from the observations during later months of the simulation with more infections by the new variants.

**Fig 5.** Estimated infection fatality risk. Red lines show the estimated median IFR with surrounding areas indicating the 50% (darker color) and 95% (lighter color) CrI. For comparison, the grey bars show the number of deaths reported for each week from the week of Oct 4, 2020 to Apr 25, 2021. X-axis labels show the week starts (mm/dd/yy).


**Table 1.** Estimated IFR for different variants and changes compared to the baseline risk estimated for preexisting variants during Oct – Dec 2020, using Eqn 4.

## Table and Figures


**Table 1.** Estimated IFR for different variants and changes compared to the baseline risk estimated for preexisting variants during Oct – Dec 2020, using Eqn 4.

Age	IFR, baseline (%)	IFR, B.1.526 (%)	IFR, B.1.1.7 (%)	Changes, B.1.526 (%)	Changes, B.1.1.7 (%)	Model goodness-of-fit (R <sup>2</sup> )
<25	0.004 (0.0021, 0.0059)	0.004 (0.0039, 0.0041)	0.004 (0.0039, 0.0042)	-0.61 (-3.5, 2.3)	0.97 (-2.8, 4.8)	1
25-44	0.04 (0.021, 0.059)	0.037 (0.034, 0.04)	0.043 (0.039, 0.047)	-6 (-13, 1.4)	8.4 (-1.9, 19)	1
45-64	0.29 (0.15, 0.44)	0.42 (0.31, 0.54)	0.51 (0.35, 0.67)	46 (7.4, 84)	76 (22, 130)	0.97
65-74	1 (0.57, 2.5)	1.9 (1.2, 2.5)	3.3 (2.4, 4.2)	82 (20, 140)	210 (130, 300)	0.96
75+	4.1 (2.2, 6.3)	6.7 (5.9, 7.4)	8 (7, 9)	62 (45, 80)	95 (71, 120)	0.99
all	0.35 (0.2, 0.58)	0.56 (0.48, 0.63)	0.72 (0.61, 0.82)	60 (38, 82)	100 (75, 130)	0.99


**Fig 1.** Study design. This study included three modeling analyses: 1) spatial network model-inference to construct the transmission dynamics and estimate key population variables and parameters by United Hospital Fund (UHF) neighborhood of residence and age group; 2) city-level multi-variant, age-structured modeling to simulate and estimate the changes in transmissibility and immune escape potential for B.1.526; and 3) linear regression models to estimate variant-specific infection fatality risk (IFR), for B.1.526 and B.1.1.7, separately. Nine datasets (listed in the black open boxes) were used as model inputs or to evaluate the accuracy of model estimates (indicated for each dataset below). Models used are shown in the blue filled boxes and model outputs are listed in the blue open boxes (key estimates reported in detail in the Results are bolded). Connections among the analyses are indicated by the arrows and associated annotations.




**Fig 2.** Model fit and key estimates. Upper panel shows model-fit to weekly number of cases (A), ED visits (B), and deaths (C), for all ages combined. Lower panel shows key model-inference estimates of weekly number of infections including those not detected as cases (D), cumulative number of infections in NYC overall (E), and cumulative infection rate by neighborhood (F). Boxes show model estimates (thick horizontal lines and box edges show the median, 25<sup>th</sup>, and 75<sup>th</sup> percentiles; vertical lines extending from each box show 95% CrI) and red dots show corresponding. For the weekly estimates, week starts (mm/dd/yy) are shown in the x-axis labels. Star (\*) in the map indicates the location of the Washington Heights – Inwood neighborhood.




**Fig 3.** Changes in transmission rate. (A) Changes in neighborhood-level relative transmission rate. (B) Changes in citywide transmission rate. Vertical dashed lines indicate the earliest date B.1.526 was identified as reported in Annavajhala et al. Labels of x-axis show the week starts (mm/dd/yy).



**Fig 4.** Comparison of different combinations of changes in transmissibility and immune escape property for B.1.526. Left panel shows the overall accuracy (A), relative RMSE (B), and correlation (C) of model estimates under different transmissibility and immune escape settings. White crosses (x) indicate the best-performing parameter combination. Right panel shows model estimates using the overall best-performing parameter combination (i.e., 1.5-3.5% initial prevalence, 15-25% higher transmissibility, and 0-10% immune escape). Lines and surrounding areas show model-simulated median estimates and interquartile range; dots show corresponding observations; colors indicate different variants as specified in the legend. Note that these model simulations used same infection-detection rate, hospitalization-rate and IFR (i.e., average during Nov 2020 – Apr 2021); that is, they did not account for changes in case ascertainment or disease severity by week during this period, due to, e.g., increases in disease severity by the new variants. As such, there were larger deviations from the observations during later months of the simulation with more infections by the new variants.



**Fig 5.** Estimated infection fatality risk. Red lines show the estimated median IFR with surrounding areas indicating the 50% (darker color) and 95% (lighter color) CrI. For comparison, the grey bars show the number of deaths reported for each week from the week of Oct 4, 2020 to Apr 25, 2021. X-axis labels show the week starts (mm/dd/yy).



### Supplemental Tables and Figures

**Table S1.** Prior ranges for the network model-inference system. The prior ranges are similar to Table S1 of Yang et al.(6) but include additional parameters in Eqn 1. The spatial, temporal, and age resolution of each parameter or variable, estimated in the model-inference system, is specified in the column "Resolution". Note posterior parameter estimates can extend outside the specified prior ranges.

Parameter/ variable	Symbo l	Resolution	Prior range	Source/rationale
Initial exposed	$E(t=0)$	neighborhood- and age- group specific, estimated for the beginning of the Week of March 1, 2020	300 – 8000 total citywide, scaled by population size for each age group and neighborhood	Large uncertainties, used very wide range
Initial infectious	$I(t=0)$	neighborhood- and age- group specific, estimated for the beginning of the Week of March 1, 2020	150 – 4000 total citywide, scaled by population size for each age group and neighborhood	Assumed to be half the initial exposed
Initial susceptible	$S(t=0)$	neighborhood- and age- group specific, estimated for the beginning of the Week of March 1, 2020	$N - E - I$	Assumed all were susceptible except for those initially exposed/infectious
Population size in each age group and neighborhood	$N$	neighborhood- and age- group specific	N/A	NYC intercensal population estimates for 2018 (40)
Citywide transmission rate	$\beta_{city}$	Citywide, age-group specific, estimated for each week	[0.5, 1] per day overall; scaled by contact rate for each age group based on contact data from the POLYMOD study(41) (averaged across 8 countries)	Based on $R_0$ estimates of around 1.5-4 for SARS- CoV-2 (42-44)
Scaling of neighborhood	$b_i$	neighborhood- and age- group specific, estimated for each week	[0.8, 1.2] for age groups under 65 years;	Around 1; larger variation for elderly groups based on data



transmission rate			[0.5, 1.5] for age groups 65 or older	
Latency period	$Z$	Citywide, age-group specific, estimated for each week	[2, 5] days	Incubation period: 5.2 days (95% CI: 4.1, 7) (42); latency period is likely shorter than the incubation period
Infectious period	$D$	Citywide, age-group specific, estimated for each week	[2, 5] days	Time from symptom onset to hospitalization: 3.8 days (95% CI: 0, 12.0) in China,(45) plus 1-2 days viral shedding before symptom onset. We did not distinguish symptomatic/asymptomatic infections.
Immunity period	$L$	Citywide, age-group specific, estimated for each week	[2.5, 3.5] years	Based on estimated immunity period for endemic human coronaviruses (see Appendix of Yang et al.(6))
Multiplicative factor for mobility; see Yang et al.(6) for detail	$m_l$	Citywide, age-group specific, estimated for each week	[1, 2] for <1 year; [0.5, 1.5] for three age groups 1-24 years; [0.1, 1.5] for age group 25-44; [1, 2.5] for age groups 45 or older	Initial model testing showed transmission rates for younger age groups were more sensitive to changes in mobility whereas the two oldest age groups were not sensitive to mobility. For age groups with contact rates lower than the average (based on the POLYMOD study (41)), we raised the diagonal elements in the mobility

				matrix to the power of the relative contact rate (<1) to account for insensitivity of transmission rate in these age groups to mobility.
Multiplicative factor for neighborhood connectivity; see Yang et al.(6) for detail	$m_2$	Citywide, age-group specific, estimated for each week	[0.5, 2]	Likely around 1 but with large uncertainties
Mean of time from viral shedding to diagnosis; see Yang et al.(6) for detail	$T_m$	Citywide, age-group specific, estimated for each week	[3, 8] days	From a few days to a week from symptom onset to diagnosis,(45) plus 1-2 days of viral shedding (being infectious) before symptom onset
Standard deviation (SD) of time from viral shedding to diagnosis; see Yang et al.(6) for detail	$T_{sd}$	Citywide, age-group specific, estimated for each week	[1, 3] days	To allow variation in time to diagnosis
Infection-detection rate; see Yang et al.(6) for detail	$r$	Citywide, age-group specific, estimated for each week	Starting from [0.001, 0.05] at time 0 and allowed to increase over time using space re-probing(46)	Large uncertainties
Infection fatality risk (IFR); see Yang et al.(6) for detail		Citywide, age-group specific, estimated for each week	[5, 15]×10 <sup>-5</sup> for ages under 25; [5, 15]×10 <sup>-4</sup> for ages 25-44; [5, 15]×10 <sup>-3</sup> for ages 45-64; [0.01, 0.1] for ages	Based on previous estimates(47) but extend to have wider ranges

---

Time from diagnosis to death; see Yang et al.(6) for detail	Citywide	65-74; [0.02, 0.2] for ages 75+; Gamma distribution with mean of 9.36 days and SD of 9.76 days	Based on $n=15,686$ COVID-19 confirmed deaths in NYC as of May 17, 2020.
ED consultation rate (EDR)	Citywide, age-group specific, estimated for each week	[0.001, 0.02] for ages under 25; [0.003, 0.03] for ages 25-44; [0.006, 0.06] for ages 45-64; [0.01, 0.15] for ages 65-74; [0.02, 0.25] for ages 75+;	Based on the ratio of total ED visits and estimated infections during March – Dec 2020
Time-from-infectiousness-to-ED or hospitalization	Citywide, for all ages	Gamma distribution with mean of [5, 7] days and SD of [2, 4] days	

---

**Table S2.** Initial conditions used to simulate co-circulation of different variants in the multi-variant, age-structured model. To partially account for changing infection-detection rate, ED-consultation rate (EDR) and IFR, for these three parameters, we used the model-inference estimates averaged over the entire simulation period (i.e. Nov 2020 – April 2021). For the initial transmission rate (for the preexisting non-VOC/VOI variants), we used the model-inference estimates averaged over the week of 10/25/2020 – the week of 11/7/2020 (i.e. the 3 weeks around the start of simulation). For the rest of model state variables and parameters, we used model-inference estimates made at the week of 10/25/2020. For B.1.1.7, we used the following ranges based on estimates from Yang and Shaman (32): 40.3 – 52.3% higher transmissibility (related to estimates for the preexisting non-VOC/VOI variants listed below) and 0 – 10% immune escape; for comparison, contact tracing data from the UK showed that B.1.1.7 was 30-50% more infectious.(37) For B.1.427/ B.1.429, we used the following ranges based on estimates from Deng et al.(38): 16 – 24% higher transmissibility and 0-10% immune escape (vs. 21.4 – 27.8% increase in transmission rate in Deng et al.(38) without accounting for changes in immunity due to potential immune escape).

variant	parameter	lower bound	upper bound
B.1.526	Low initial prevalence (%)	0.5	2.5
B.1.526	High initial prevalence (%)	1.5	3.5
B.1.526	Wide initial prevalence (%)	0.5	3.5
B.1.1.7	Increase in transmission rate	0.403	0.5227
B.1.1.7	Immune escape	0	0.1
B.1.427/9	Increase in transmission rate	0.16	0.24
B.1.427/9	Immune escape	0	0.1
non-VOC/VOI	Travel-related importation $\epsilon_i$	Nominally set to 1 per week for the entire city (N = 8.4 million people)	
B.1.526	Travel-related importation $\epsilon_i$	Set to 0 as it emerged locally	
B.1.1.7	Travel-related importation $\epsilon_i$	For the entire city (N = 8.4 million), set to 1 per 2 days for 11/1 – 11/15/20 to reflect lower initial seeding, 1.5 per day for 11/16 -12/31/20 to reflect higher seeding during the holidays, and 2 per day for 1/1 – 4/30/21 to reflect higher seeding due to increases in these variants in the US. Same settings were used for B.1.1.7 and B.1.427/9, because once local transmission is established, travel-related importation plays a nominal role.	
B.1.427/9	Travel-related importation $\epsilon_i$		
non-VOC/VOI	$\beta_{11}$ (per day, same below)	0.14	0.21
non-VOC/VOI	$\beta_{22}$	0.15	0.2
non-VOC/VOI	$\beta_{33}$	0.16	0.22

non-VOC/VOI	$\beta_{44}$	0.16	0.23
non-VOC/VOI	$\beta_{55}$	0.24	0.36
non-VOC/VOI	$\beta_{66}$	0.17	0.25
non-VOC/VOI	$\beta_{77}$	0.17	0.22
non-VOC/VOI	$\beta_{88}$	0.19	0.25
non-VOC/VOI	$\beta_{12}$	0.071	0.1
non-VOC/VOI	$\beta_{13}$	0.018	0.027
non-VOC/VOI	$\beta_{14}$	0.0074	0.011
non-VOC/VOI	$\beta_{15}$	0.023	0.034
non-VOC/VOI	$\beta_{16}$	0.011	0.015
non-VOC/VOI	$\beta_{17}$	0.0075	0.011
non-VOC/VOI	$\beta_{18}$	0.0052	0.0075
non-VOC/VOI	$\beta_{21}$	0.074	0.1
non-VOC/VOI	$\beta_{23}$	0.019	0.026
non-VOC/VOI	$\beta_{24}$	0.0078	0.011
non-VOC/VOI	$\beta_{25}$	0.024	0.033
non-VOC/VOI	$\beta_{26}$	0.011	0.015
non-VOC/VOI	$\beta_{27}$	0.0079	0.011
non-VOC/VOI	$\beta_{28}$	0.0054	0.0074
non-VOC/VOI	$\beta_{31}$	0.02	0.028
non-VOC/VOI	$\beta_{32}$	0.02	0.028
non-VOC/VOI	$\beta_{34}$	0.0098	0.014
non-VOC/VOI	$\beta_{35}$	0.013	0.018
non-VOC/VOI	$\beta_{36}$	0.0072	0.01
non-VOC/VOI	$\beta_{37}$	0.0051	0.0071
non-VOC/VOI	$\beta_{38}$	0.0066	0.0091
non-VOC/VOI	$\beta_{41}$	0.0085	0.013
non-VOC/VOI	$\beta_{42}$	0.0085	0.013
non-VOC/VOI	$\beta_{43}$	0.013	0.02
non-VOC/VOI	$\beta_{45}$	0.014	0.021
non-VOC/VOI	$\beta_{46}$	0.01	0.015
non-VOC/VOI	$\beta_{47}$	0.0037	0.0054
non-VOC/VOI	$\beta_{48}$	0.0069	0.01
non-VOC/VOI	$\beta_{51}$	0.11	0.17
non-VOC/VOI	$\beta_{52}$	0.11	0.17
non-VOC/VOI	$\beta_{53}$	0.092	0.14
non-VOC/VOI	$\beta_{54}$	0.073	0.11
non-VOC/VOI	$\beta_{56}$	0.07	0.11
non-VOC/VOI	$\beta_{57}$	0.042	0.064
non-VOC/VOI	$\beta_{58}$	0.041	0.062

non-VOC/VOI	$\beta_{61}$	0.053	0.076
non-VOC/VOI	$\beta_{62}$	0.053	0.076
non-VOC/VOI	$\beta_{63}$	0.043	0.063
non-VOC/VOI	$\beta_{64}$	0.051	0.074
non-VOC/VOI	$\beta_{65}$	0.053	0.076
non-VOC/VOI	$\beta_{67}$	0.058	0.084
non-VOC/VOI	$\beta_{68}$	0.052	0.076
non-VOC/VOI	$\beta_{71}$	0.032	0.041
non-VOC/VOI	$\beta_{72}$	0.032	0.041
non-VOC/VOI	$\beta_{73}$	0.022	0.028
non-VOC/VOI	$\beta_{74}$	0.0096	0.012
non-VOC/VOI	$\beta_{75}$	0.023	0.029
non-VOC/VOI	$\beta_{76}$	0.032	0.042
non-VOC/VOI	$\beta_{78}$	0.066	0.085
non-VOC/VOI	$\beta_{81}$	0.028	0.036
non-VOC/VOI	$\beta_{82}$	0.028	0.036
non-VOC/VOI	$\beta_{83}$	0.03	0.038
non-VOC/VOI	$\beta_{84}$	0.022	0.028
non-VOC/VOI	$\beta_{85}$	0.027	0.034
non-VOC/VOI	$\beta_{86}$	0.047	0.06
non-VOC/VOI	$\beta_{87}$	0.073	0.093
all	$Z_1$ (days, same below)	2.9	4
all	$Z_2$	3.3	4.3
all	$Z_3$	3.4	4.4
all	$Z_4$	3.4	4.4
all	$Z_5$	3.5	4.4
all	$Z_6$	3.5	4.5
all	$Z_7$	3.3	4.2
all	$Z_8$	3.3	4.2
all	$D_1$	2.1	2.9
all	$D_2$	2.7	3.6
all	$D_3$	3.2	4.1
all	$D_4$	3.4	4.4
all	$D_5$	3.1	4.1
all	$D_6$	3.2	4.2
all	$D_7$	2.8	3.7
all	$D_8$	2.5	3.3
all	$IFR_1$	3.10E-05	5.00E-05
all	$IFR_2$	3.00E-05	4.90E-05
all	$IFR_3$	3.10E-05	4.90E-05

all	IFR <sub>4</sub>	3.00E-05	4.90E-05
all	IFR <sub>5</sub>	3.00E-04	0.00048
all	IFR <sub>6</sub>	0.0029	0.004
all	IFR <sub>7</sub>	0.013	0.016
all	IFR <sub>8</sub>	0.046	0.055
all	EDR <sub>1</sub>	0.0087	0.013
all	EDR <sub>2</sub>	0.0059	0.0084
all	EDR <sub>3</sub>	0.0023	0.0033
all	EDR <sub>4</sub>	0.0046	0.006
all	EDR <sub>5</sub>	0.01	0.012
all	EDR <sub>6</sub>	0.019	0.023
all	EDR <sub>7</sub>	0.031	0.039
all	EDR <sub>8</sub>	0.057	0.07
all	<i>Infection detection rate, r<sub>1</sub></i>	0.14	0.19
all	<i>Infection detection rate, r<sub>2</sub></i>	0.21	0.26
all	<i>Infection detection rate, r<sub>3</sub></i>	0.23	0.29
all	<i>Infection detection rate, r<sub>4</sub></i>	0.28	0.34
all	<i>Infection detection rate, r<sub>5</sub></i>	0.39	0.47
all	<i>Infection detection rate, r<sub>6</sub></i>	0.36	0.42
all	<i>Infection detection rate, r<sub>7</sub></i>	0.33	0.41
all	<i>Infection detection rate, r<sub>8</sub></i>	0.34	0.41


---

**Table S3.** Estimated IFR for different variants and changes compared to the baseline risk estimated for preexisting variants during Oct – Dec 2020, using Eqn 3.


Age	IFR, baseline (%)	IFR, B.1.526 (%)	Changes, B.1.526 (%)	Model fit, R <sup>2</sup>
<25	0.004 (0.0021, 0.0059)	0.004 (0.0038, 0.0041)	-0.03 (-3.8, 3.8)	1
25-44	0.04 (0.021, 0.059)	0.035 (0.031, 0.038)	-12 (-21, -3.1)	0.97
45-64	0.29 (0.15, 0.44)	0.42 (0.24, 0.59)	43 (-17, 100)	0.67
65-74	1 (0.57, 2.5)	1.5 (0.53, 2.5)	46 (-50, 140)	0.46
75+	4.1 (2.2, 6.3)	6.1 (5.1, 7)	47 (25, 69)	0.94
all	0.35 (0.2, 0.58)	0.5 (0.4, 0.61)	43 (13, 73)	0.89



**Fig S1.** Estimated infection-detection rate by age group. Red lines show the estimated median infection-detection rate with surrounding areas indicating the 50% (darker color) and 95% (lighter color) CrI. For comparison, the grey bars show the number of cases reported for each week from the week of Oct 4, 2020 to Apr 25, 2021. Labels of x-axis show the week starts (mm/dd/yy).



**Fig S2.** Model-fit by age group. Boxes show model estimates (thick horizontal lines and box edges show the median, 25<sup>th</sup>, and 75<sup>th</sup> percentiles; vertical lines extending from each box show 95% CrI) and red dots show corresponding



**Fig S3.** Estimated cumulative infection rates by age group. Thick horizontal lines and box edges show the median, 25<sup>th</sup>, and 75<sup>th</sup> percentiles; vertical lines extending from each box show 95% CrI.

